However, high doses of IL-15 can induce cytokine release syndrome (CRS) in patients with advanced acute myeloid leukemia (AML) and dose-limiting toxicity in patients with malignant melanoma or renal cell carcinoma [44,45]. Here, IL15 is linked to acute myeloid leukemia.